420 Stevens Avenue, Suite 370
25 articles with Leading Biosciences
The combined company, Palisade Bio, Inc., is expected to commence trading on the Nasdaq Capital Market under the ticker symbol “PALI” on April 28, 2021
- Proposed merger with Leading Biosciences, Inc. expected to close on or about Tuesday, April 27th, 2021
Leading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label Study
Leading BioSciences, Inc., a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc., subject to certain conditions to be completed, to form Palisade Bio, Inc., announced data from an open label GI surgery study with lead asset LB1148 that provided an early indication of efficacy signal in reducing post-surgical adhesions following elective bowel resection.
Leading BioSciences Provides Update to Seneca Biopharma, Inc. Stockholders on Merger Closing Process Following Virtual Special Meeting on April 23, 2021 and Upcoming Milestones Following Planned Close of Merger
Video message details merger closing process following completion of the April 23 virtual Special Meeting as well as next planned milestones for the merged company to be renamed Palisade Bio As of April 19, 2021, based on voting indications, Proposal 1 is expected to be approved at the Special Meeting completing the transaction.
Leading BioSciences Releases Video Message Encouraging Seneca Biopharma, Inc. Stockholders to Vote at the Virtual Special Meeting on April 23, 2021
Video messages urges Seneca stockholders to vote in support of Proposal #1, the reverse stock split, in order to approve the proposed transaction.
Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc.
Leading BioSciences, Inc. (“LBS”), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today released a video message from its CEO, Tom Hallam, highlighting the many compelling attributes of the proposed merger with Seneca Biopharma, Inc.
Combined company, to be named Palisade Bio, will be well-positioned to leverage its compelling therapeutics pipeline, strong cash position, and accomplished management and Board to maximize stockholder value
The management of Seneca Biopharma, Inc. and Leading BioSciences, Inc. have each received inquiries regarding Seneca's special meeting of stockholders that was convened on March 24, 2021 and adjourned to April 9, 2021.
Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (Nasdaq: SNCA) to form Palisade Bio, Inc., today announced that the Company will present at the upcoming H.C. Wainwright Global Life Sciences Conference, which is being held virtually from March 9-10, 2021.
Leading BioSciences Announces FDA Fast Track Designation Granted to LB1148 for the Treatment of Postoperative Gastrointestinal Dysfunction Associated with Pediatric Cardiovascular SurgeryLBS expects to initiate a pivotal trial in 2021
Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (Nasdaq: SNCA) to form Palisade Bio, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to LB1148 for the treatment of postoperative gastrointestinal (GI) dysfunction associated with pediatric heart surgery. “Even with high success ra
Combined Company to be Named Palisade Bio Creating Nasdaq-listed Company Focused on Advancing Leading BioSciences' Clinical Programs
Leading BioSciences Teams with Donnelley Financial Solutions to Create Innovative Study Tool for Clinical Trial Monitoring During COVID-19 Pandemic
Novel application will enable Leading BioSciences to remotely monitor phase 2 study data in patients with COVID-19 pneumonia
Leading BioSciences Receives IND Clearance for Phase 2 COVID-19 StudyLB1148 Now Available for Investigational Use to Treat Pulmonary Dysfunction Associated with COVID-19 Pneumonia
Leading BioSciences, Inc. (LBS), a drug development company focused on improving human health through therapeutic protection of the intestinal mucosal barrier, today announced the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a phase 2 study of its lead investigational drug, LB1148 for the “treatment of pulmonary dysfunction associated with COVID-19 pneumonia.” The study will i
Leading BioSciences Announces Potential for Investigational Drug LB1148 to Treat Multiple Organ Dysfunction Syndrome in COVID-19 PatientsCompany Publishes White Paper Outlining Potential Use of LB1148 to Alleviate Strain on the Healthcare System
Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the intestinal mucosal barrier, today announced it has developed a potential approach to treat COVID-19 patients suffering from acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) using its investigational drug LB1148. COVID-19 poses a serious global threat to patients and the healthcare
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
Leading BioSciences Announces Top Line Phase 2 Data Demonstrating LB1148 Achieves Primary Endpoint with Statistically Significant Improvement in Bowel Function Following Cardiovascular Surgery
Data Demonstrate Efficacy on an Approvable Endpoint That May Also Result in Substantial Cost Savings Based on Reductions ICU and Hospital Length of Stay
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
Leading BioSciences Reports Positive Interim Results from Phase 2 Trial of LB1148 in Patients Undergoing Major Surgery
Leading BioSciences today reported positive interim data from the company’s ongoing Phase 2 clinical trial of its lead drug candidate, LB1148.
Leading Biosciences Launches Gastrobiome Focused Product Development Strategy To Harness Microbiome Ecosystem In The Gastrointestinal Tract